相似文献
1
Substrate activity screening with kinases: discovery of small-molecule substrate-competitive c-Src inhibitors.
Angew Chem Int Ed Engl. 2014 Jul 1;53(27):7010-3. doi: 10.1002/anie.201311096. Epub 2014 May 2.
2
Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain.
Bioconjug Chem. 2016 Jul 20;27(7):1745-9. doi: 10.1021/acs.bioconjchem.6b00243. Epub 2016 Jun 22.
3
Exquisitely specific bisubstrate inhibitors of c-Src kinase.
ACS Chem Biol. 2015 Jun 19;10(6):1387-91. doi: 10.1021/cb501048b. Epub 2015 Mar 31.
4
Application of a Substrate-Mediated Selection with c-Src Tyrosine Kinase to a DNA-Encoded Chemical Library.
Molecules. 2019 Jul 30;24(15):2764. doi: 10.3390/molecules24152764.
5
Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.
ACS Chem Biol. 2012 Nov 16;7(11):1910-7. doi: 10.1021/cb300337u. Epub 2012 Sep 5.
6
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Chem Biol Drug Des. 2006 Jan;67(1):46-57. doi: 10.1111/j.1747-0285.2005.00316.x.
7
ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases.
Bioorg Med Chem. 2004 Nov 15;12(22):5753-66. doi: 10.1016/j.bmc.2004.08.043.
8
Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors.
Methods Mol Biol. 2017;1636:79-89. doi: 10.1007/978-1-4939-7154-1_6.
9
Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK).
Eur J Med Chem. 2022 Feb 5;229:114051. doi: 10.1016/j.ejmech.2021.114051. Epub 2021 Dec 16.
10
Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
ACS Chem Biol. 2013 Dec 20;8(12):2734-43. doi: 10.1021/cb400663k. Epub 2013 Oct 29.
引用本文的文献
1
The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance.
Chem Sci. 2024 Jul 13;15(33):13130-13147. doi: 10.1039/d4sc01088d. eCollection 2024 Aug 22.
2
Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases.
CNS Drugs. 2021 Jan;35(1):1-20. doi: 10.1007/s40263-020-00787-5. Epub 2021 Jan 30.
3
Application of a Substrate-Mediated Selection with c-Src Tyrosine Kinase to a DNA-Encoded Chemical Library.
Molecules. 2019 Jul 30;24(15):2764. doi: 10.3390/molecules24152764.
4
Fluorogenic structure activity library pinpoints molecular variations in substrate specificity of structurally homologous esterases.
J Biol Chem. 2018 Sep 7;293(36):13851-13862. doi: 10.1074/jbc.RA118.003972. Epub 2018 Jul 13.
5
Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain.
Bioconjug Chem. 2016 Jul 20;27(7):1745-9. doi: 10.1021/acs.bioconjchem.6b00243. Epub 2016 Jun 22.
6
Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
ACS Chem Biol. 2016 May 20;11(5):1296-304. doi: 10.1021/acschembio.5b01018. Epub 2016 Mar 1.
7
Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration.
ACS Med Chem Lett. 2015 Jul 13;6(8):898-901. doi: 10.1021/acsmedchemlett.5b00167. eCollection 2015 Aug 13.
8
Exquisitely specific bisubstrate inhibitors of c-Src kinase.
ACS Chem Biol. 2015 Jun 19;10(6):1387-91. doi: 10.1021/cb501048b. Epub 2015 Mar 31.
9
Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method.
J Am Chem Soc. 2015 Mar 18;137(10):3616-21. doi: 10.1021/jacs.5b00095. Epub 2015 Mar 5.
10
Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.
ACS Chem Biol. 2015 Jan 16;10(1):175-89. doi: 10.1021/cb5008376. Epub 2014 Dec 23.
本文引用的文献
1
Metrics other than potency reveal systematic variation in responses to cancer drugs.
Nat Chem Biol. 2013 Nov;9(11):708-14. doi: 10.1038/nchembio.1337. Epub 2013 Sep 8.
2
The Substrate-Activity-Screening methodology applied to receptor tyrosine kinases: a proof-of-concept study.
Eur J Med Chem. 2012 Nov;57:1-9. doi: 10.1016/j.ejmech.2012.08.038. Epub 2012 Sep 4.
3
Development of a highly selective c-Src kinase inhibitor.
ACS Chem Biol. 2012 Aug 17;7(8):1393-8. doi: 10.1021/cb300172e. Epub 2012 Jun 4.
4
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
Cancer Lett. 2012 Jul 1;320(1):104-10. doi: 10.1016/j.canlet.2012.01.039. Epub 2012 Feb 2.
5
Comprehensive analysis of kinase inhibitor selectivity.
Nat Biotechnol. 2011 Oct 30;29(11):1046-51. doi: 10.1038/nbt.1990.
6
Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
Future Med Chem. 2011 Jan;3(1):29-43. doi: 10.4155/fmc.10.272.
7
ADP-Glo: A Bioluminescent and homogeneous ADP monitoring assay for kinases.
Assay Drug Dev Technol. 2009 Dec;7(6):560-72. doi: 10.1089/adt.2009.0222.
8
Bisubstrate inhibitors of protein kinases: from principle to practical applications.
ChemMedChem. 2010 Jan;5(1):23-34. doi: 10.1002/cmdc.200900252.
9
Targeting cancer with small molecule kinase inhibitors.
Nat Rev Cancer. 2009 Jan;9(1):28-39. doi: 10.1038/nrc2559.
10
Small molecule recognition of c-Src via the Imatinib-binding conformation.
Chem Biol. 2008 Oct 20;15(10):1015-22. doi: 10.1016/j.chembiol.2008.09.007.
Zotero 插件